From:	(b)(3):10 USC 424; (b)(6)
To:	
CC:	
Subject:	FW: Hydroxychloroquine and azithromycin drug combination tasker response
Date:	2020/04/01 19:33:19
Priority:	Normal
Type:	Note

## Classification: UNCLASSIFIED

\_\_\_\_

## (b)(3):10 USC 424; (b)(6)

The FAQ submission below was approved by OCC and OGC and is approved to be posted.

R,


(b)(3):10 USC 424; (b)(6)


om:		
	April 1, 2020 1:14 PM	
]	(b)(3):10 USC 424; (b)(6)	

Classification: UNCLASSIFIED

OCC: no objections.

(Perhaps add one of the serious side effects? I think I read: ....heart attacks.)






OGC has no legal objection.

b)(3):10 USC 424; (b)(6)	

WARMAGE This e-mail and any attachments may be protected by the attorney-client privilege or attorney work product privilege and may also contain FOIA exempt information. This information is intended for use only by the individual or entity to which it is addressed. If you are not the intended recipient or employee or agent responsible for delivering the e-weil to the intended recipient, any dissemination, distribution, copying or use of this e-mail or its contents for once, than official purposes is strictly prohibited. If you have received this e-mail in error, please notify the sender immediately by replying to this message and immediately destroy all copies of this e-mail. Unauthorized disclosure or misuse of this information may result in legal penalties.



Classification: UNCLASSIFIED

ALCON. Please review write-up below for legal and language and return to me for posting on FAQs.

Thanks

Re: Hydroxychloroquine and azithromycin drug combination tasker response

BLUF: There appears to be a benefit in terms of recovery and blunted viral replication with this combination therapy, but the data are very preliminary and will need to be confirmed in larger randomized clinical trials. It should also be noted that hydroxychloroquine does have some serious side effects that must be considered.

On 28 March, the FDA issued an Emergency Use Authorization (EUA) for both chloroquine and hydroxylchloroquine at the request of Dr. Rick Bright, Director of the Biomedical Advanced Research and Development Authority at the Department of Health and Human Services. The use is limited to a valid clinical indication described in the EUA, a valid prescription from a licensed practitioner, and sourcing from the Strategic National Stockpile.

Limited testing with this combination therapy has resulted in promising but very preliminary results. The individual efforts described below are two small studies showing a positive benefit, a summary of Chinese clinical experience, and a larger planned clinical study to be conducted in Australia.

One study

(https://www.sciencedirect.com/science/article/pii/s0924857920300 996?via%3dihub) with a small cohort (34 patients total) concluded that "Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin."

- A description of the summary of Chinese clinical evidence (no data shown) makes similar claims ( <u>https://www.jstage.jst.go.jp/article/bst/14/1/14\_2020.&#65279;01047/\_pdf/-</u> char/en)
- Another small study showing some benefit from combination therapy (https://www.medrxiv.org/content/10.1101/2020.03.22.20040949v1.full.&#65 279;pdf)
- A larger study is being planned in Australia (<u>https://www.uq.edu.&#65279;au/news/article/2020/03/researchers-set-beginclinical-trials-potential-coronavirus-treatment</u>).

Please let me know if you have any additional questions or if I can be of further help.

R,

## (b)(3):10 USC 424; (b)(6)

Classification: UNCLASSIFIED

Classification: UNCLASSIFIED

Classification: UNCLASSIFIED

Classification: UNCLASSIFIED

Classification: UNCLASSIFIED

Sender: Recipient:	(b)(3):10 USC 424; (b)(6)
Sent Date:	2020/04/01 19:33:04
Delivered Date:	2020/04/01 19:33:19